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The accumulation of insoluble proteins is a pathological hallmark of several neurodegenerative disorders. Tauopathies are
caused by the dysfunction and aggregation of tau protein and an impairment of cellular protein degradation pathways may
contribute to their pathogenesis. Thus, a deﬁciency in autophagy can cause neurodegeneration, while activation of autophagy is
protective against some proteinopathies. Little is known about the role of autophagy in animal models of human tauopathy.
In the present report, we assessed the effects of autophagy stimulation by trehalose in a transgenic mouse model of tauopathy,
the human mutant P301S tau mouse, using biochemical and immunohistochemical analyses. Neuronal survival was evaluated
by stereology. Autophagy was activated in the brain, where the number of neurons containing tau inclusions was signiﬁcantly
reduced, as was the amount of insoluble tau protein. This reduction in tau aggregates was associated with improved neuronal
survival in the cerebral cortex and the brainstem. We also observed a decrease of p62 protein, suggesting that it may contribute
to the removal of tau inclusions. Trehalose failed to activate autophagy in the spinal cord, where it had no impact on the level of
sarkosyl-insoluble tau. Accordingly, trehalose had no effect on the motor impairment of human mutant P301S tau transgenic
mice. Our ﬁndings provide direct evidence in favour of the degradation of tau aggregates by autophagy. Activation of autophagy
may be worth investigating in the context of therapies for human tauopathies.
Keywords: autophagy; neurodegenerative disorders; neuroprotection; protein aggregation; tau
Abbreviation: LC3 = microtubule-associated protein light chain 3
Introduction
Most neurodegenerative diseases are characterized by the accu-
mulation of misfolded proteins. Thus, -synuclein aggregates
in Parkinson’s disease and other synucleinopathies, TDP-43 (TAR
DNA-binding protein 43) in TDP-43 proteinopathies, huntingtin in
Huntington’s disease and both b-amyloid and tau in Alzheimer’s
disease (Goedert et al., 2010). Filaments made of hyperpho-
sphorylated tau protein are a good predictor of the cognitive
state in Alzheimer’s disease, because a negative correlation has
been described between the number of neuroﬁbrillary tangles,
and the Mini-Mental score (Giannakopoulos et al., 2003).
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several other diseases, including progressive supranuclear palsy,
corticobasal degeneration, Pick’s disease and frontotemporal de-
mentia and parkinsonism linked to chromosome 17 (Goedert and
Jakes, 2005; Goedert and Spillantini, 2011). Since ﬁlament
assembly is a concentration-dependent process, a reduction in
the production and/or increased clearance of tau are potential
targets.
In eukaryotic cells, there are two major systems responsible for
the degradation of cytoplasmic proteins: the ubiquitin–proteasome
system and the autophagy–lysosome pathway (Goldberg, 2003).
The accumulation of ubiquitinated tau in intracellular ﬁlamentous
inclusions suggests a possible impairment of tau degradation by
the ubiquitin–proteasome system and/or the autophagy–lysosome
pathway. Indeed, inactivation of the ubiquitin–proteasome system
or the autophagy–lysosome pathway has been reported to lead to
neurodegeneration associated with the presence of ubiquitinated
aggregates (Hara et al., 2006; Komatsu et al., 2006; Bedford
et al., 2008; Riley et al., 2010). Particularly, ubiquitin–proteasome
system or autophagy–lysosome pathway inhibition induces the
accumulation of tau (Blard et al., 2006; Ramesh Babu et al.,
2008; Liu et al., 2009; Lee et al., 2010). Moreover, accumulation
of autophagic vacuoles has been observed in Alzheimer’s disease
brain and in a mouse model of tauopathy (Lin et al., 2003; Nixon
et al., 2005), suggesting a possible disturbance of lysosomal
proteolysis in tauopathy. Macroautophagy (hereafter referred to
as autophagy) is the major form of autophagy. Although it is
known that the suppression of autophagy causes neurodegenera-
tion (Hara et al., 2006), relatively little is known about the role of
autophagy in animal models of human tauopathy. In the triple
transgenic mouse model of Alzheimer’s disease and in a mouse
model expressing human mutant tau on a null background for the
E3 ubiquitin ligase parkin, stimulation of autophagy promoted the
degradation of insoluble tau (Caccamo et al., 2011; Majumder
et al., 2011; Rodriguez-Navarro et al., 2011). However, these
studies did not allow one to determine whether the effects of
autophagy stimulation were due to a direct interaction between
the autophagic machinery and tau or whether they were indirect.
To date, there has been no report of the effect of increased
autophagy in a mouse model of human tauopathy. We therefore
administered trehalose, a mammalian target of rapamycin
(mTOR)-independent activator of autophagy (Noda and Ohsumi,




We used phosphorylation-independent anti-tau antibodies BR133
and BR134 which recognize both murine and human tau isoforms.
Phosphorylation-dependent anti-tau antibodies AT8 and AT100
(Innogenetics) were also used. AT8 recognizes tau protein phosphory-
lated at S202 and T205 (Goedert et al., 1995), whereas AT100
detects tau phosphorylated at T212, S214 and T217 (Yoshida and
Goedert, 2006). Autophagy was assessed using an antibody against
microtubule-associated protein light chain 3 (LC3) (Novus Biologicals).
We also used an antibody against p62/SQSTM1 (Santa Cruz
Biotechnology). To normalize protein levels, an anti-GAPDH
(Millipore, Ltd.) antibody was used.
Animals and treatment
Homozygous human P301S tau transgenic mice (Allen et al., 2002)
and age-matched wild-type C57BL/6 mice were used (n = 6 per
group for western blot analysis; n = 3 per group for immunohisto-
chemistry and stereology experiments). From weaning onwards, the
animals were treated with 2% trehalose or 2% sucrose, which were
used as the control. A separate group received normal drinking
water (no treatment). The water solutions were changed twice
weekly. Animals were checked daily and the quantity of water
drunk and the animals’ weights were assessed twice a week.
P301S tau transgenic mice develop motor deﬁcits at 3–4 months
of age, as shown using Rotarod (Scattoni et al., 2010). We routinely
evaluated these deﬁcits by visual inspection, as they form in a
stereotypical manner consisting of an unstable gait followed by gen-
eral stiffness and hindlimb paralysis. Furthermore, at 3–4 months of
age, the human P301S tau mice are unable to extend their hind-
limbs when lifted by the tail (Allen et al., 2002). In this study, we
assessed the motor deﬁcits by visual inspection and used the time
when all the animals had developed hindleg stiffness and were
unable to extend their hindlimbs when suspended by the tail as
the endpoint (20 weeks of age).
Tissue extraction
To extract sarkosyl-insoluble proteins from brain and spinal cord,
frozen tissues were weighed and homogenized in cold extraction
buffer [10 mM Tris–HCl, pH 7.4, 800mM NaCl, 1mM EGTA, 0.1M
phenylmethylsulphonyl ﬂuoride, 10% sucrose and one tablet of
complete protease inhibitor cocktail (Roche)]. The homogenates
were spun at 6000g for 20min and the supernatants incubated with
1% sarkosyl for 1h at room temperature. After a 1h centrifugation at
80000g, the supernatants were discarded and the pellets resuspended
in 50mM Tris–HCl, pH 7.4 (300ml/g tissue). For investigation of
soluble tau, brains and spinal cords were homogenized in 25mM
Tris–HCl, pH 7.4, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1mM
phenylmethylsulphonyl ﬂuoride and one tablet of complete protease
inhibitor cocktail. Samples were centrifuged at 80000g for 15min.
The resulting supernatant constituted the soluble fraction. The samples
were analysed by SDS-PAGE.
Immunoblot analysis
After SDS-PAGE, the gels were blotted for 1h at room temperature
onto polyvinylidene diﬂuoride membranes (Millipore). The membranes
were blocked for 1h at room temperature in 0.1M phosphate buffer,
pH 7.4, 0.2% Tween 20 and 5% milk, followed by an overnight
incubation with the primary antibody in blocking buffer. Membranes
were then washed in 0.1M phosphate buffer, pH 7.4, 0.2% Tween 20
and incubated for 1h at room temperature with peroxidase-
conjugated secondary antibody (Pierce) in blocking solution. After
washing, the blots were developed using enhanced chemiluminescence
(Amersham Biosciences).
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Band intensities were quantiﬁed (Chemidoc
TM XRS and Quantity One
software, Bio-Rad) and the amounts of soluble proteins normalized
with respect to GAPDH. Insoluble tau was normalized relative to the
tissue weight. Data were expressed as means  SEM. Statistical
analysis was performed using a one-way ANOVA test followed by
Tukey’s post hoc comparisons (Prism, GraphPad Software, Inc.).
Immunohistochemistry
Mice were perfused transcardially with 4% paraformaldehyde in 0.1M
phosphate buffer, pH 7.4. Brains and spinal cords were dissected and
post-ﬁxed overnight at 4C, followed by cryoprotection in PBS con-
taining 30% sucrose for at least 24h. Serial sagittal brain sections
(30mm) were cut on a Leica SM2400 microtome (Leica
Microsystems) and stored at 4C in PBS containing 0.1% sodium
azide. For ﬂuorescence labelling, sections were permeabilized for
5min with cold PBS containing 0.5% Triton X-100 and washed
three times with PBS, 0.1% Triton X-100 (PBST). After 2h blocking
at room temperature with PBST containing 3% bovine serum albumin,
sections were incubated with the primary antibodies in blocking solu-
tion for 24h at 4C. This was followed by three washes and a 2h
incubation at room temperature with Alexa Fluor 488 (Molecular
Probes) or Cy5 (Abcam) secondary antibodies in blocking solution.
After washing and DAPI (4,6-diamidino-2-phenylindole) staining, the
sections were mounted using Vectashield mounting medium (Vector
Laboratories). They were analysed using a Leica DMRB ﬂuorescence
microscope (Leica) or a Radiance 2100 confocal microscope (Bio-Rad).
Images were taken using a Sharp 2000 laser (Zeiss Bio-Rad) and were
typically 512  512 pixels. Staining for neuronal nuclei (NeuN;
Chemicon) (Mullen et al., 1992; Wolf et al., 1996; Lind et al.,
2005) and tau phosphorylated at the AT100 epitope were carried
out in brains of wild-type and transgenic mice using immunoperoxi-
dase (Vectastain ABC kit, Vector Laboratories). Endogenous peroxidase
was quenched for 15min with 3% H2O2 in distilled water. After
washing, sections were blocked for 1h with normal horse serum in
PBST and incubated overnight with the anti-NeuN antibody (1:500) in
blocking solution at 4C. After three rinses with PBST, sections were
incubated with a biotin-conjugated anti-mouse antibody for 2h at
room temperature. Next, the avidin–biotin-conjugated complex was
applied for a further 2h. Finally, the antigen was visualized using
the Vector VIP substrate kit (Vector Laboratories). Sections were
mounted on SuperFrost glass slides (VWR international) and dehy-
drated using a series of ascending ethanol solutions (70, 95 and
100%) and xylene.
Stereology
The Stereo Investigator 9 (MBF Bioscience) was used to quantify the
number of NeuN-positive cells. Sections through the brain were
sampled in a systematic random manner using 1:12 series for quanti-
ﬁcation of NeuN-positive and AT100-positive neurons. The thickness
of each section was determined using the Stereo Investigator 9 soft-
ware. For a given section, the outline of the region of interest was
traced under a 10 objective and the enclosed area calculated by the
software. Sections within the highlighted area were then sampled at
random and cells counted under the 40 objective to determine the
total number of immunoreactive cells. Statistical analyses were
performed using a one-way ANOVA test followed by Tukey’s
post hoc comparisons (Prism, GraphPad Software, Inc.).
Results
Animal health
Water consumption of the three groups (no treatment,
sucrose-treated and trehalose-treated) was similar. Sucrose and
trehalose had no impact on the animals’ weights or coat aspects,
suggesting that the health of the mice was similar among the
three groups. The human P301S tau mice were sacriﬁced at
20 weeks of age, when they developed an unstable gait and
motor abnormalities, which is typical of homozygous transgenic
mice (Allen et al., 2002). The development of motor deﬁcits
was not signiﬁcantly different between treated and non-treated
human P301S tau transgenic mice. Thus, untreated mice
developed the ﬁrst motor deﬁcits at 19  0.19 weeks of age,
which was not signiﬁcantly different from the ages at which
they appeared in sucrose-treated (18.8  0.31 weeks) and
trehalose-treated (19.25  0.23 weeks) mice (Supplementary
Fig. 1).
Effects of trehalose on autophagy
activation
To investigate autophagy activation, we measured the conversion
of LC3-I into LC3-II, a marker of autophagic vacuole formation
(Kabeya et al., 2000; Mizushima et al., 2004; Tanida et al., 2004).
We observed the conversion of 17.5  2.3% LC3-I into LC3-II in
the brains of trehalose-treated mice, while no detectable LC3-I
conversion was seen in untreated or sucrose-treated mice
(Fig. 1A). Unexpectedly, trehalose had no effect on LC3-I conver-
sion in the spinal cord (Fig. 1B). We therefore focused our study
on the brain. Immunohistochemistry of brain sections from mice
transgenic for human mutant P301S tau showed the presence
of LC3 puncta in trehalose-treated mice (Fig. 1E). The punctate
distribution of LC3 was absent from control groups (Fig. 1C and
D). In trehalose-treated transgenic mice, AT100-positive tau
aggregates were also immunoreactive for LC3, indicating the
co-localization of autophagic vacuoles and tau aggregates
(arrows, Fig. 1F–H).
Effects of trehalose on tau pathology
and neuronal survival
Total soluble tau and soluble tau phosphorylated at the AT8 epi-
tope were not affected by trehalose treatment (Supplementary
Fig. 2). In contrast, quantiﬁcation of sarkosyl-insoluble tau in the
brain indicated that trehalose decreased the amount of insoluble
tau compared with untreated controls (53%, P50.01) or to
controls treated with sucrose (46%, P50.05) (Fig. 2A).
Trehalose treatment had no effect on the amount of sarkosyl-
insoluble tau in the spinal cord (Fig. 2B). Immunoﬂuorescence
staining for anti-tau antibody AT100 showed a drastic reduction
in the number of positive cells in layers I–III of the cerebral cortex
(66.5% compared with untreated animals, P50.01; 80.1%
compared with sucrose-treated mice, P50.001) (Fig. 2C–F)
and in the brainstem, particularly the pontine nucleus
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compared with sucrose-treated mice, P50.01) (Fig. 2G–J).
Nerve cell numbers were counted in layers I–III of the cerebral
cortex and in the pontine nucleus. The number of neurons in
layers I–III was higher in trehalose-treated P301S tau mice than
in animals that received either no treatment (+55.5%, P50.05)
or were treated with sucrose (+59.6%, P50.05) (Fig. 3A).
The number of neurons in trehalose-treated mice and in untreated
wild-type animals was not signiﬁcantly different (Fig. 3A). In
the pontine nucleus, the number of neurons increased in
trehalose-treated animals compared with untreated (+79.2%,
P50.01) and sucrose-treated controls (+61.6%, P50.05)
(Fig. 3B). The number of NeuN-positive cells in the pontine
nucleus was similar in trehalose-treated P301S tau mice and in
wild-type controls (Fig. 3B).
Effects of trehalose on p62/SQSTM1
Immunohistochemistry revealed the co-localization of p62/
SQSTM1 and AT100-positive tau aggregates in P301S tau
transgenic mice (Fig. 4D–F), while no co-staining was observed
in wild-type controls (Fig. 4A–C). We assessed the levels of
p62/SQSTM1 in the brains of wild-type and transgenic P301S
tau mice subjected to the different treatments. We observed
a reduction in p62/SQSTM1 levels in mice treated with trehalose
compared with mice that received either no treatment (52.1%,
P50.05) or sucrose (46.7%, P50.05) (Fig. 4G). No signiﬁcant
difference was detected between wild-type controls and P301S
tau transgenic mice (Fig. 4G).
Discussion
The assembly of normally soluble proteins into amyloid-like ﬁbrils
is a pathological hallmark of several neurodegenerative disorders,
with tauopathies being the most common (Goedert et al., 2010).
Herein, we report on the effects of stimulation of autophagy on
tau inclusions and nerve cell survival in a mouse line transgenic for
human mutant P301S tau. Trehalose activated autophagy in the
brain, as shown by the increased formation of LC3-II, and reduced
Figure 1 Conversion of LC3-I into LC3-II was assessed by western blotting in the spinal cord (A) and the brain (B) of mice transgenic for
human P301S tau. LC3-II staining was only present in brain where autophagic vacuoles were observed in trehalose-treated mice (arrow in
E). Autophagic vacuoles were not present in the brains of non-treated (C) or sucrose-treated (D) mice. (F–H) Confocal analysis indicated
that AT100-positive tau inclusions (F) were also immunoreactive for LC3-II (G), suggesting the presence of tau inclusions in autophagic
vacuoles in trehalose-treated transgenic mice (H). NT = no treatment; Su = sucrose-treated; Tr = trehalose-treated. Scale bar = 20mm.
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autophagy in the spinal cord and consequently had no effect on
the level of insoluble tau. The mechanism of action of trehalose is
not completely understood, but it is believed to activate autop-
hagy in an mTOR-independent manner (Sarkar et al., 2007a).
These ﬁndings suggest that autophagic pathways may differ
between brain and spinal cord. The absence of a detectable
effect of trehalose in the spinal cord probably accounted for the
persistence of a pathological motor phenotype in treated P301S
tau transgenic mice. We cannot exclude that a detailed behav-
ioural assessment could have revealed subtle differences between
treated and non-treated mice. However, the motor deﬁcit charac-
teristic of the human P301S tau transgenic mice probably results
from the degeneration of spinal cord motor neurons, consequent
to the development of a toxic ﬁlamentous tau pathology (Allen
et al., 2002; Delobel et al., 2008), and possibly the sequestration
of proteins important for motor behaviour. As tau pathology in
the spinal cord was unchanged after trehalose administration,
an improvement in motor function was unlikely. The reasons
underlying our inability to activate autophagy in the spinal cord
remain to be determined. They could be related to a less efﬁcient
delivery of trehalose to the spinal cord, although it has been
shown that the blood–spinal cord barrier is more permeable to
tracers and cytokines than the blood–brain barrier (Prockop
et al., 1995; Pan et al., 1997). We hope that future experiments
will allow us to overcome this limitation.
Figure 2 Sarkosyl-insoluble tau was decreased in the brain of trehalose-treated mice compared with non-treated or sucrose-treated
animals (A), while trehalose treatment had no effect on sarkosyl-insoluble tau in the spinal cord (B). In trehalose-treated mice, the number
of nerve cells with AT100-positive inclusions was drastically reduced in layers I–III of the cerebral cortex (C–F) and in the pontine nucleus
of the brainstem (G–J). NT = no treatment; Su = sucrose-treated; Tr = trehalose-treated. *P50.05, **P50.01 and ***P50.001.
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in sarkosyl-insoluble tau and the number of nerve cells with tau
inclusions. Besides its ability to activate autophagy, trehalose has
also been reported to act as a protective chaperone in a murine
model of Huntington’s disease (Tanaka et al., 2004). However,
the reduction in tau inclusions in our mouse line was probably
due to the degradation of tau aggregates by trehalose-induced
autophagy. Indeed, we observed a decrease in tau inclusions
only in regions where autophagy was activated. Moreover, we
showed co-localization between autophagic vacuoles and tau
inclusions, suggesting that tau aggregates were engulfed by
autophagosomes before degradation. Sucrose, a chemical
chaperone, which has been shown to reduce the conversion of
the cellular prion protein to its protease-resistant form
(DebBurman et al., 1997), failed to reduce tau aggregates in the
human mutant P301S tau transgenic mice, conﬁrming that the
effect of trehalose on tau aggregates was mediated through an
increase in autophagy.
Altogether, our results indicate that the in vivo stimulation of
autophagy reduced the amount of tau aggregates and improved
nerve cell survival. A role for autophagy in the clearance of protein
aggregates has been suggested for a number of proteins, including
b-amyloid, -synuclein, ataxin-3, prion protein and huntingtin
(Webb et al., 2003; Sarkar et al., 2007b; Pickford et al., 2008;
Figure 3 Nerve cell numbers were assessed using stereology. Trehalose treatment increased the number of neurons in layers I–III of the
cerebral cortex (A) and in the pontine nucleus of the brainstem (B). *P50.05 and **P50.01.
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2011; Riedel et al., 2011; Spilman et al., 2011). Activation of
autophagy has also shown protective effects in mouse and ﬂy
models of tauopathy (Berger et al., 2006; Caccamo et al., 2011;
Majumder et al., 2011; Rodriguez-Navarro et al., 2011).
However, in mice, tau was not the only engineered protein. In
one study, the mice overexpressed human mutant tau and carried
a deletion of the gene encoding parkin (Rodriguez-Navarro et al.,
2011), a potential mediator of autophagy (Olzmann et al., 2007;
Chin et al., 2011). Therefore, not surprisingly, restoration of
autophagic activity decreased the number of tau aggregates and
improved cell survival. In separate studies, autophagy was acti-
vated in triple transgenic mice exhibiting tau and b-amyloid
pathologies (Caccamo et al., 2011; Majumder et al., 2011). It is
well established that b-amyloid can promote tau pathology in
some brain regions (Go ¨tz et al., 2001; Lewis et al., 2001;
Oddo et al., 2003, 2004). However, direct evidence for the
relevance of autophagy in modulating tau pathology was missing.
We now show that the activation of autophagy markedly reduced
the number of tau aggregates and nerve cell loss in a mouse
model of human tauopathy.
We also investigated p62/SQSTM1 expression in wild-type and
P301S tau transgenic mice. p62/SQSTM1 is a protein that acts as
a receptor for selective autophagy, mainly because of its ability to
bind both ubiquitin and LC3 (Pankiv et al., 2007; Lamark et al.,
2009). It has previously been implicated in the degradation of
protein inclusions (Bjorkoy et al., 2006; Watanabe and Tanaka,
2011) and has been found in tau inclusions in human
Figure 4 Immunohistochemistry for p62/SQSTM1 (A and D) and assembled tau (AT100; B and E) showed co-localization in P301S tau
transgenic mice (F) but not in wild-type animals (C). Scale bar = 20mm. (G) Western blot of p62/SQSTM1 levels in the brains of wild-type
controls and mice transgenic for human mutant P301S tau that received either no treatment or were given sucrose or trehalose. The
amount of p62/SQSTM1 signal is shown normalized with respect to GAPDH. *P50.05 and **P50.01.
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et al., 2002). We now show co-localization of p62/SQSTM1 with
tau inclusions in P301S tau transgenic mice, consistent with the
human pathology. In addition, we observed a decrease in
p62/SQSTM1 levels in trehalose-treated mice, suggesting that
p62/SQSTM1 may be an adaptor molecule for tau inclusions
before their degradation by autophagy. Although the majority of
tau ﬁlaments in P301S tau transgenic are not ubiquitinated
(Allen et al., 2002), p62/SQSTM1 may nonetheless be involved,
as it has been shown to play a role in the autophagic degradation
of non-ubiquitinated protein aggregates (Watanabe and Tanaka,
2011). The levels of p62/SQSTM1 were similar between P301S
tau transgenic mice and wild-type controls, indicating that
p62/SQSTM1 synthesis and basal autophagy were not affected
in the transgenic mice. In conclusion, we show that activation of
autophagy in mice transgenic for human mutant P301S tau
decreased the number of tau inclusions and increased nerve cell
survival in cerebral cortex and brainstem.
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